Detail Information of Exogenous Modulation
| General Information of Drug Transporter (DT) | |||||
|---|---|---|---|---|---|
| DT ID | DTD0531 Transporter Info | ||||
| Gene Name | KCNH7 | ||||
| Transporter Name | Voltage-gated potassium channel Kv11.3 | ||||
| Gene ID | |||||
| UniProt ID | |||||
| Exogenous factors (drugs, dietary constituents, etc.) Modulation of This DT (EGM) | |||||
|---|---|---|---|---|---|
Chemical Compound |
|||||
DT Modulation1 |
NOG protein co-treated with Valproic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide results in increased expression of KCNH7 mRNA | [8] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
DT Modulation1 |
Benzo(a)pyrene results in increased methylation of KCNH7 3' UTR | [9] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
DT Modulation2 |
Benzo(a)pyrene results in increased methylation of KCNH7 exon | [9] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
DT Modulation3 |
Benzo(a)pyrene results in increased methylation of KCNH7 promoter | [9] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
DT Modulation4 |
Benzo(a)pyrene results in increased mutagenesis of KCNH7 gene | [10] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide |
2 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide results in increased expression of KCNH7 mRNA | [8] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
DT Modulation2 |
NOG protein co-treated with Valproic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide results in increased expression of KCNH7 mRNA | [8] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
bisphenol S |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
bisphenol S results in decreased methylation of KCNH7 gene | [11] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
dorsomorphin |
2 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide results in increased expression of KCNH7 mRNA | [8] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
DT Modulation2 |
NOG protein co-treated with Valproic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide results in increased expression of KCNH7 mRNA | [8] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
Levonorgestrel |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
testosterone undecanoate co-treated with Levonorgestrel results in increased expression of KCNH7 mRNA | [12] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
methyleugenol |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
methyleugenol results in decreased expression of KCNH7 mRNA | [7] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
N-Nitrosopyrrolidine |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
N-Nitrosopyrrolidine results in decreased expression of KCNH7 mRNA | [7] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
Okadaic Acid |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Okadaic Acid results in decreased expression of KCNH7 mRNA | [13] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
Phenylmercuric Acetate |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide results in increased expression of KCNH7 mRNA | [8] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
Silicon Dioxide |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Silicon Dioxide analog results in increased expression of KCNH7 mRNA | [14] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
sodium arsenite |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
sodium arsenite results in increased expression of KCNH7 mRNA | [4] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
testosterone undecanoate |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
testosterone undecanoate co-treated with Levonorgestrel results in increased expression of KCNH7 mRNA | [12] | |||
Regulation Mechanism |
Transcription Factor Info | ||||
Approved Drug |
|||||
Acetaminophen |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Acetaminophen inhibits the expression of KCNH7 | [1] | |||
Doxorubicin |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Doxorubicin inhibits the expression of KCNH7 | [2] | |||
Valproic Acid |
2 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Valproic Acid increases the expression of KCNH7 | [3] | |||
Drug in Phase 3 Trial |
|||||
Triclosan |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Triclosan inhibits the expression of KCNH7 | [6] | |||
Drug in Phase 1 Trial |
|||||
Sodium arsenite |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Sodium arsenite increases the expression of KCNH7 | [4] | |||
Drug in Preclinical Test |
|||||
(+)-JQ1 |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
(+)-JQ1 inhibits the expression of KCNH7 | [5] | |||
Natural Product |
|||||
Methyleugenol |
1 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Methyleugenol inhibits the expression of KCNH7 | [7] | |||
Carcinogen |
|||||
Benzo(a)pyrene |
5 DT Activity Modulations Related to This Exogenous Factor | Click to Show/Hide the Full List | |||
DT Modulation1 |
Benzo(a)pyrene inhibits the expression of KCNH7 | [7] | |||
If you find any error in data or bug in web service, please kindly report it to Dr. Li and Dr. Fu.